{"id":"taurolidine-heparin","safety":{"commonSideEffects":[{"rate":null,"effect":"Local catheter site reactions"},{"rate":null,"effect":"Bleeding or hematoma at insertion site"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL2105420","moleculeType":"Small molecule","molecularWeight":"284.36"},"_dailymed":{"setId":"13b3a61e-5a4b-4afb-8fa1-d76ebdb344d6","title":"DEFENCATH (TAUROLIDINE AND HEPARIN) SOLUTION [CORMEDIX INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Taurolidine is a broad-spectrum antimicrobial that disrupts bacterial cell membranes and prevents biofilm formation on catheter surfaces, while heparin provides anticoagulant activity to prevent thrombotic occlusion. This combination is used as a catheter lock solution to reduce catheter-related bloodstream infections and maintain patency in central venous catheters and hemodialysis access devices.","oneSentence":"Taurolidine heparin is a combination antimicrobial and anticoagulant agent that prevents bacterial biofilm formation and thrombosis in vascular access devices.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:16.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of catheter-related bloodstream infections in central venous catheters"},{"name":"Maintenance of hemodialysis catheter patency"},{"name":"Prevention of thrombosis in vascular access devices"}]},"trialDetails":[{"nctId":"NCT07366372","phase":"NA","title":"Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-05-01","conditions":"Taurolidine, Lock Solution, Prevention","enrollment":120},{"nctId":"NCT06822426","phase":"PHASE3","title":"Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)","status":"RECRUITING","sponsor":"CorMedix","startDate":"2025-05-14","conditions":"Central Line Associated Blood Stream Infections (CLABSI)","enrollment":200},{"nctId":"NCT06714864","phase":"PHASE4","title":"Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age","status":"RECRUITING","sponsor":"CorMedix","startDate":"2025-07-08","conditions":"Catheter-Related Infections","enrollment":36},{"nctId":"NCT07074821","phase":"PHASE2","title":"Antimicrobial Locks for Hemodialysis Catheter Infections","status":"COMPLETED","sponsor":"Oman Ministry of Health","startDate":"2023-03-01","conditions":"Catheter Related Blood Stream Infection, Hemodialysis, Vascular Access","enrollment":100},{"nctId":"NCT02651428","phase":"PHASE3","title":"Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection","status":"COMPLETED","sponsor":"CorMedix","startDate":"2015-12","conditions":"Kidney Failure, Chronic, Catheter-Related Infections","enrollment":806},{"nctId":"NCT06707480","phase":"","title":"Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials","status":"AVAILABLE","sponsor":"CorMedix","startDate":"","conditions":"Catheter-related Bloodstream Infection","enrollment":""},{"nctId":"NCT05740150","phase":"NA","title":"Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients.","status":"UNKNOWN","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2020-10-27","conditions":"Central Line-associated Bloodstream Infection (CLABSI)","enrollment":462},{"nctId":"NCT01243710","phase":"PHASE4","title":"Taurolidine in Haemodialysis Catheter Related Bacteraemia","status":"COMPLETED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2010-08","conditions":"Renal Dialysis, Catheter-Related Infections","enrollment":27},{"nctId":"NCT03539718","phase":"PHASE4","title":"Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters.","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2018-05-15","conditions":"Hemodialysis Catheter Infection, Thrombosis; Dialysis Catheter","enrollment":60},{"nctId":"NCT02036255","phase":"PHASE3","title":"Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2015-05","conditions":"Patency, Infection","enrollment":68},{"nctId":"NCT02789501","phase":"PHASE4","title":"Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-01","conditions":"Catheter Infections, End-stage Renal Disease","enrollment":106},{"nctId":"NCT02868697","phase":"PHASE4","title":"Management of Tunneled Catheter Thrombosis in Hemodialysis Patients: Prospective Study From Qatar","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2013-11","conditions":"Hemodialysis, Tunneled Catheter, Qatar","enrollment":170},{"nctId":"NCT01948245","phase":"PHASE4","title":"Clinical Trial Comparing Catheter Lock Solutions TaurolockTMHep 100 and Heparin 100 IE/ml.","status":"UNKNOWN","sponsor":"Palle Bekker Jeppesen","startDate":"2013-10","conditions":"Catheter-related Bloodstream Infection (CRBSI) Nos","enrollment":42},{"nctId":"NCT02515201","phase":"PHASE4","title":"Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-09","conditions":"Catheter-Related Infections","enrollment":20},{"nctId":"NCT00735813","phase":"PHASE3","title":"Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2008-04","conditions":"Bacteremia, Neoplasms","enrollment":129},{"nctId":"NCT00749619","phase":"PHASE3","title":"Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?","status":"COMPLETED","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2007-05","conditions":"End Stage Renal Disease, Hemodialysis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tautolock HEP 500","Taurolock HEP 500"],"phase":"marketed","status":"active","brandName":"Taurolidine heparin","genericName":"Taurolidine heparin","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Taurolidine heparin is a combination antimicrobial and anticoagulant agent that prevents bacterial biofilm formation and thrombosis in vascular access devices. Used for Prevention of catheter-related bloodstream infections in central venous catheters, Maintenance of hemodialysis catheter patency, Prevention of thrombosis in vascular access devices.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}